Chemoembolization in colorectal liver metastases: The rebirth

Anticancer Research

Volumn 34, Issue 2, 2014, Pages 575-584

  Fiorentini, Giammaria ^a   Aliberti, Camillo ^b   Mulazzani, Luca ^c   Coschiera, Paolo ^c   Catalano, Vincenzo ^a   Rossi, David ^a   Giordani, Paolo ^a   Ricci, Stefano ^d  

^a Azienda Ospedaliera Ospedali Riuniti Marche Nord   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c Azienda Ospedaliera Ospedali Riuniti Marche Nord   (Italy)

^d INRCA   (Italy)

Author keywords

Aflibercept; Cetuximab; Chemoembolization; Colorectal cancer; DEBIRI; Drug eluting beads; Irinotecan; KRAS; Liver metastases; Regorafenib; Review

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; DOXORUBICIN; IRINOTECAN; REGORAFENIB; CETUXIMAB;

CANCER CONTROL; CHEMOEMBOLIZATION; CLINICAL RESEARCH; COLORECTAL LIVER METASTASIS; COLORECTAL TUMOR; EMBOLIC PARTICLE; HUMAN; HYPOXIA; LIVER CANCER; LIVER CELL CARCINOMA; LIVER METASTASIS; NEUROENDOCRINE TUMOR; PERSONAL EXPERIENCE; PRACTICE GUIDELINE; QUALITY OF LIFE; RADIOLOGIST; REVIEW; SALVAGE THERAPY; TRANSARTERIAL CHEMOEMBOLIZATION; TREATMENT DURATION; TREATMENT OUTCOME; COLORECTAL CANCER; DEBIRI; DRUG-ELUTING BEADS; KRAS; LIVER METASTASES; LIVER TUMOR; METASTASIS; METHODOLOGY; PATHOLOGY;

AFLIBERCEPT; CETUXIMAB; CHEMOEMBOLIZATION; COLORECTAL CANCER; DEBIRI; DRUG-ELUTING BEADS; IRINOTECAN; KRAS; LIVER METASTASES; REGORAFENIB; REVIEW;

CHEMOEMBOLIZATION, THERAPEUTIC; COLORECTAL NEOPLASMS; HUMANS; LIVER NEOPLASMS;

EID: 84897069642     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Hagar FA and Boushey RP: Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 22: 191-197, 2009.
2. Boyle P and Ferlay J: Cancer incidence and mortality in Europe 2004. Ann Oncol 16: 481-488, 2005.
3. Figueras J, Torras J, Valls C, Llado L, Ramos E, Marti-Ragué J, Serrano T and Fabregat J: Surgical resection of colorectal liver metastases in patients with expanded indications: A single-center experience with 501 patients. Dis Colon Rectum 50: 478-488, 2007.
4. Choti MA, Sitzman JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ and Cameron JL: Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235: 759-766, 2002.
5. Abdalla Ek, VautheyJN, Ellis LM,Ellis V, Pollock R, Broglio KR, Hess K and Curley SA: Recurrences and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239: 818-825, 2004.
6. Borner M, Castiglione M and Bacchi M: The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: Results of a phase III trial. Ann Oncol 9: 535-541, 1998.
7. Machover D: A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer 80: 1179-1187,1997.
8. Goldberg R, Sargent D, Morton R, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22(1): 3-30, 2004.
9. Alberts S, Horvath W and Sternfeld W: Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group phase II study. J Clin Oncol 23: 9243-9249, 2005.
10. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M and Masi G: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (Folfoxiri) compared with infusional fluorouracil,leucovorin, and irinotecan (Folfiri) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol 25: 1670-1676, 2007.
11. Hurwitz H, Fehrenbacher L and Novotny W: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
12. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I and Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345, 2004.
13. Saltz L, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F and Cassidy J: Bevacizumab in combination with oxaliplatinbased chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26(12): 2013-2019, 2008.
14. Van Cutsem E, Koehne C, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J and Rougier P: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. New Engl J Med 360(14): 1408-1417, 2009.
15. Chen HX, Mooney M, Boron M,Vena D, Mosby K, Grochow L, Jaffe C, Rubinstein L, Zwiebel J and Kaplan RS: Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI treatment referral center trial TRC-0301. J Clin Oncol 24(21): 3354-3360, 2006.
16. Nordlinger B, Van Cutsem E, Rougier P,.Köhne CH, Ychou M, Sobrero A, Adam R, Arvidsson D, Carrato A, Georgoulias V, Giuliante F, Glimelius B, Golling M, Gruenberger T, Tabernero J, Wasan H and Poston G: Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 43: 2037-2045, 2007.
17. Wicherts DA, de Haas RJ, Salloum C, Andreani P, Pascal G, Sotirov D, Adam R, Castaing D and Azoulay D: Repeat hepatectomy for recurrent colorectal metastases. Br J Surg 100(6): 808-818, 2013.
18. Cleary JM, Tanabe KT, Lauwers GY and Zhu AX: Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver. Oncologist 14(11): 1095-1105, 2009.
19. Stillwell AP, Ho YH and Veitch C: Systematic review of prognostic factors related to overall survival in patients with stage IV colorectal cancer and unresectable metastases. World J Surg 35: 684-692, 2011.
20. Lewandowski R, Geschwind J and Liapi E: Transcatheter intraarterial therapies: Rationale and overview. Radiology 259: 641-657, 2011.
21. Liapi E and Geschwind J: Chemoembolization for primary and metastatic liver cancer. Cancer J 16: 156-162, 2010.
22. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K and Takashima S: Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148: 397-401, 1983.
23. Yamada R, Nakatsuka H and Nakamura K: Hepatic artery embolization in 32 patients with unresectable hepatoma. Osaka City Med J 26: 81-96, 1980.
24. Collins JM: Pharmacologic rationale for regional drug delivery. J Clin Oncol 2: 498-504, 1984.
25. Coldwell D, Stokes K and Yakes W: Embolotherapy: Agents, clinical applications, and techniques. RadioGraphics 14: 623-643, 1994.
26. Taylor R, Tang Y, Gonzalez M, Stratford P and Lewis A: Irinotecan drug-eluting beads for use in chemoembolization: In vitro and in vivo evaluation of drug release properties. Eur J Pharm Sci 30(1): 7-14, 2007.
27. Varela M, Real MI, Burrel M Forner A, Sala M, Brunet M, Ayuso C, Castells L, Montañá X, Llovet JM and Bruix J: Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46(3): 474-481, 2007.
28. Llovet J, Real M and Montana X: Arterial embolisation or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 359: 1734-1739, 2002.
29. Tellez C, Benson A and Lyster M: Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer 82: 1250-1259, 1998.
30. Bavisotto L, Patel N, Althaus S, Coldwell DM, Nghiem HV, Thompson T, Storer B and Thomas CR Jr.: Hepatic transcatheter arterial chemoembolization alternating with systemic protracted continuous infusion 5-fluorouracil for gastrointestinal malignancies metastatic to liver: A phase II trial of the Puget Sound Oncology Consortium (PSOC 1104). Clin Cancer Res 5(1): 95-109, 1999.
31. Hong K, McBride J, Georgiades C, Reyes DK, Herman JM, Kamel IR and Geschwind JF: Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. J Vasc Interv Radiol 20(3): 360-367, 2009.
32. Albert M, Kiefer M, Sun W, Haller D, Fraker DL, Tuite CM, Stavropoulos SW, Mondschein JI and Soulen MC: Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer 117(2): 343-352, 2011.
33. Nishiofuku H, Tanaka T, Matsuoka M, Otsuji T, Anai H, Sueyoshi S, Inaba Y, Koyama F, Sho M, Nakajima Y and Kichikawa K: Transcatheter arterial chemoembolization using cisplatin powder mixed with degradable starch microspheres for colorectal liver metastases after FOLFOX failure: Results of a phase I/II study. J Vasc Interv Radiol 24(1): 56-65, 2013.
34. Vogl TJ, Gruber T, Balzer JO, Eichler K, Hammerstingl R and Zangos S: Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. Radiology 250(1): 281-289, 2009.
35. Sanz-Altamira PM, Spence LD, Huberman MS, Posner MR, Steele G Jr., Perry LJ and Stuart KE: Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial. Dis Colon Rectum 40(7): 770-775, 1997.
36. Salman HS, Cynamon J, Jagust M, Bakal C, Rozenblit A, Kaleya R, Negassa A and Wadler S: Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver. Clin Colorectal Cancer 2(3): 173-179, 2002.
37. Hunt T, Flowerdew A, Birch S, Williams J, Mullee M and Taylor I: Prospective randomized controlled trial of hepatic arterial embolization or infusion chemotherapy with 5-fluorouracil and degradable starch microspheres for colorectal liver metastases. Br J Surg 77(7): 779-782, 1990.
38. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology - Colon Carcinoma, version 1. Fort Washington, PA: NCCN, 2013.
39. Lammer J, Malagari K, Vogl T. Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, Benhamou Y, Avajon Y, Gruenberger T, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P and Lencioni R: Prospective randomized study of doxorubicin eluting-bead embolization in the treatment of hepatocellular carcinoma: Results of the PRECISION V study. Cardiovasc Intervent Radiol 33(1): 41-52, 2010.
40. Martin R, Scoggins C, Tomalty D, Schreeder M, Metzger T, Tatum C and Sharma V: Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: Results of pharmacokinetics and phase I trial. J Gastrointest Surg 16(8): 1531-1538, 2012.
41. Aliberti C, Fiorentini G, Muzzio PC, Pomerri F, Tilli M, Dallara S and Benea G: Transarterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC bead, drug-eluting bead loaded with irinotecan: results of a phase II clinical study. Anticancer Res 31(12): 4581-4587, 2011.
42. Martin R, Joshi J and Robbins K: Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: Results of multi-institutional study. Ann Surg Oncol 18(1): 192-198, 2010.
43. Eichler K, Zangos S, Mack MG, Hammerstingl R, Gruber-Rouh T, Gallus C and Vogl TJ: First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI). Int J Oncol 41(4): 1213-20, 2012.
44. Fiorentini G, Aliberti C, Turrisi G, Del Conte A, Rossi S, Benea G and Giovanis P: Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecaneluting beads: results of a phase II clinical study. In Vivo 21(6): 1085-1091, 2007.
45. Fiorentini G, Aliberti C, Tilli M, Mulazzani L, Graziano F, Giordani P, Mambrini A, Montagnani F, Alessandroni P, Catalano V and Coschiera P: Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: Final results of a phase III study. Anticancer Res 32: 1387-1396, 2012.
46. Hicklin DJ and Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027, 2005.
47. Kerbel RS: Tumor angiogenesis. N Eng J Med 358: 2039-2049, 2008.
48. Islam R, Chyou PH and Burmester JK: Modeling efficacy of bevacizumab treatment for metastatic colon cancer. J Cancer 4(4): 330-335, 2013.
49. Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T and Kubicka S: Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML 18147): A randomized phase III trial. Lancet Oncol 14: 29-37, 2013.
50. Fischer C, Mazzone M, Jonckx B and Carmeliet P: FLT1 and its ligands VEGFB and PlGF: Drug targets for antiangiogenic therapy ? Nat Rev Cancer 8: 942-956, 2008.
51. Gaya A and Tse V: A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat Rev 38: 484-493, 2012.
52. Holash J, Davis S, Papadopoulos N,Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD and Rudge JS: VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99: 11393-11398, 2002.
53. Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK and Jaffe RB: Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 11: 6966-6971, 2005.
54. Cheng YD, Yang H, Chen GQ and Zhang ZC: Molecularly targeted drugs for metastatic colorectal cancer. Drug Des Devel Ther 1;7: 1315-1322, 2013.
55. Lockhart AC, Rothenberg ML, Dupont J, Cooper W, Chevalier P, Sternas L, Buzenet G, Koehler E, Sosman JA, Schwartz LH, Gultekin DH, Koutcher JA, Donnelly EF, Andal R, Dancy I, Spriggs DR and Tew WP: Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 28: 207-214, 2010.
56. Khayat D, Tejpar S, Spano JP, Verslype C, Bloch J, Vandecaveye V, Assadourian S, Soussan-Lazard K, Cartot-Coton S and Van Cutsem E: Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I study. Eur J Cancer 49(4): 790-797, 2013.
57. Marques I, Araújo A and de Mello RA: Anti-angiogenic therapies for metastatic colorectal cancer: Current and future perspectives. World J Gastroenterol 28;19(44): 7955-7971, 2013.
58. Van Cutsem E, Khayat D, Verslype C, Billemont B, Tejpar S, Meric JB, Soussan-Lazard K, Assadourian S, Cartot-Cotton S and Rixe O: Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours. Eur J Cancer 49: 17-24, 2013.
59. Van Cutsem E,Tabernero J, Lakomy R. Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R and Allegra C: Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30: 3499-506, 2012.
60. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G and Trail PA: BAY 43-9006 exhibits broadspectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-109, 2004.
61. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, Thierauch KH and Zopf D: Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129: 245-55, 2011.
62. Waddell T and Cunningham D: Evaluation of regorafenib in colorectal cancer and GIST. Lancet 381: 273-275, 2013.
63. Wehler TC, Hamdi S, Maderer A, Graf C, Gockel I, Schmidtmann I, Hainz M, Berger MR, Theobald M, Galle PR, Moehler M and Schimanski C: Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft-no benefit of combination therapy. Int J Colorectal Dis 28: 385-398, 2013.
64. Mross K, Frost A, Steinbild S, Hedbom S, Büchert M, Fasol U, Unger C, Krätzschmar J, Heinig R, Boix O and Christensen O: A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 18: 2658-2667, 2012.
65. Strumberg D, Scheulen ME, Schultheis B, Richly H, Frost A, Büchert M, Christensen O, Jeffers M, Heinig R, Boix O, Mross K. Regorafenib (BAY 73-4506) in advanced colorectal cancer: A phase I study. Br J Cancer 106: 1722-1727, 2012.
66. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase III trial. Lancet 381(9863): 303-312, 2013.
67. Richardson AJ, Laurence JM and Lam VW: Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review. J Vasc Interv Radiol 24(8): 1209-1217, 2013.